The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Firm, enables the generic company to produce and sell atazanavir, along with didanosine and stavudine, in sub-Saharan Africa and India ?incredible effect . Atazanavir can be an important element of HIV combination therapy and this agreement facilitates broader option of the medicine to help ensure patients can access appropriate treatment regimens. The immunity-from-suit contract with Matrix Laboratories is the fifteenth agreement that Bristol-Myers Squibb offers signed because of its HIV medications, and the fourth for atazanavir. A key component of the contract is the inclusion of pediatric formulations of the medicines to support the procedure needs of kids with HIV.
These reviews will be distributed to the HBV and HCV community to enhance the body of knowledge on hepatitis prevention, treatment, and support. Related StoriesUsing integrated molecular pathology to manage incidental pancreatic cysts: an interview with Dr Ananya DasDeaths from avoidable risk elements: an interview with Dr Ali Mokdad, IHMEScar management: an interview with Adele Atkinson, Associate Professor, College of NursingChinese Grant Recipient Aims to Inform HCV Public Policy Approximately 40 million people are infected with HCV in China, leading the Chinese authorities to declare it an urgent public health issue.